Patton Albertson Miller Group LLC Increases Position in Eli Lilly and Company (NYSE:LLY)

Patton Albertson Miller Group LLC lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 32.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 823 shares of the company’s stock after acquiring an additional 200 shares during the quarter. Patton Albertson Miller Group LLC’s holdings in Eli Lilly and Company were worth $480,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Inspire Advisors LLC purchased a new stake in Eli Lilly and Company during the third quarter worth about $226,000. Gratus Capital LLC increased its stake in shares of Eli Lilly and Company by 7.8% during the 3rd quarter. Gratus Capital LLC now owns 3,286 shares of the company’s stock worth $1,765,000 after purchasing an additional 237 shares during the last quarter. AlphaQ Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 3rd quarter worth approximately $292,000. BSW Wealth Partners lifted its stake in Eli Lilly and Company by 13.3% in the third quarter. BSW Wealth Partners now owns 3,167 shares of the company’s stock valued at $1,701,000 after purchasing an additional 371 shares during the last quarter. Finally, Capital Advisors Ltd. LLC grew its holdings in Eli Lilly and Company by 3.5% during the third quarter. Capital Advisors Ltd. LLC now owns 1,347 shares of the company’s stock valued at $723,000 after purchasing an additional 45 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a research report on Wednesday, February 21st. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Wells Fargo & Company boosted their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. BMO Capital Markets raised their price objective on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a report on Wednesday, May 1st. Finally, Morgan Stanley boosted their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $757.95.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock traded down $3.45 during mid-day trading on Thursday, hitting $771.55. 2,169,264 shares of the company traded hands, compared to its average volume of 3,068,803. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. Eli Lilly and Company has a one year low of $419.80 and a one year high of $800.78. The stock has a market cap of $733.28 billion, a price-to-earnings ratio of 113.63, a price-to-earnings-growth ratio of 1.45 and a beta of 0.37. The stock has a fifty day moving average price of $761.56 and a 200-day moving average price of $675.58.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm’s revenue was up 26.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.62 EPS. On average, equities analysts predict that Eli Lilly and Company will post 13.82 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.67%. The ex-dividend date is Wednesday, May 15th. Eli Lilly and Company’s payout ratio is currently 76.58%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.